Publication
Global rules on foreign direct investment (FDI)
Cross-border acquisitions and investments increasingly trigger foreign direct investment (FDI) screening requirements.
United States | Publication | July 2024
The Joint Commission has released new and revised requirements applicable to behavioral healthcare and human services (BHC) organizations that use restraint and/or seclusion. In their announcement, The Joint Commission stated that “[p]hysical holding restraints can be as dangerous as other types of restraint and should be held to the same requirements, as evidenced by a study that examined data collected over 26 years regarding restraint fatalities among children and adolescents in the United States.” Because this standard is effective immediately, facilities should confirm compliance with the requirement and be prepared to address and remedy any noncompliance existing at the time of their next survey.
The Joint Commission is updating the definition of “restraint” in the glossary of the Comprehensive Accreditation Manual for Behavioral Health Care and Human Services:
Restraint is any method (chemical or physical) of restricting the freedom of movement of an individual served to manage their behavior. This includes any manual method, physical or mechanical device, material or equipment that immobilizes or reduces the ability of an individual to move their arms, legs, body or head freely. It also includes any drug or medication when it is used as a restriction to manage the individual’s behavior or to restrict their freedom of movement and is not a standard treatment or dosage for their condition.
Examples of what is not considered a restraint is also included:
The changes to the Comprehensive Accreditation Manual for Behavioral Health Care and Human Services affect any BHC organization accredited by The Joint Commission and provide best practices for other entities.
Norton Rose Fulbright lawyers will continue to follow updates from The Joint Commission.
Publication
Cross-border acquisitions and investments increasingly trigger foreign direct investment (FDI) screening requirements.
Publication
On February 2, 2024, the Belgian Presidency of the Council of the European Union confirmed that the Committee of Permanent Representatives had signed the Artificial Intelligence (AI) Regulation, referred to as the AI Act. Approval by the EU Parliament followed on 13 March 2024, and the AI Act is likely to appear in the EU’s Official Journal around May 2024. The AI Act aims to establish a stringent legal framework governing the development, marketing, and utilisation of artificial intelligence within the region, thereby marking a significant advancement in the regulation of this burgeoning domain.
Publication
The EU’s Artificial Intelligence Regulation, commonly referred to as the AI Act, is expected to come into force during the summer of 2024 (the AI Act). The AI Act will be the first comprehensive legal framework for the use and development of artificial intelligence (AI), and is intended to ensure that AI systems developed and used in the EU are safe, transparent, traceable, non-discriminatory and environmentally friendly.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023